Teduglutide (Revestive®) for the treatment of short bowel syndrome
The Minister of Health, Welfare and Sport (VWS) has asked Zorginstituut Nederland to carry out an assessment of teduglutide (Revestive®). This was in response to a request from the marketing authorisation holder to include this drug in the Medicine Reimbursement System (GVS). Zorginstituut Nederland has carried out the assessment of the medicinal product teduglutide (Revestive®), after being advised by the Scientific Advisory Board (WAR).
Results and advice
Zorginstituut Nederland has concluded that for the treatment of short bowel syndrome with chronic type III intestinal failure, the therapeutic value of teduglutide is lower than that of placebo, when both are given in addition to best supportive care. Although a reduction in parenteral support (at least 20% volume reduction) is measured in the group of teduglutide-users, patients remain dependent on a degree of parenteral nutrition. Furthermore, it is not clear to what extent the effects measured are the result of natural adaptation. No difference in quality of life can be demonstrated between the group treated with teduglutide and the control group.
Based on the results of the assessment, Zorginstituut Nederland advises against including teduglutide (Revestive®) in the GVS.
This report is a summary of recommendations by Zorginstituut Nederland. The original text of this excerpt is in Dutch.